Akari Therapeutics PLCNASDAQ:AKTX
- LAST PRICE1.3000
- TODAY'S CHANGE (%)0.0600 (4.8387%)
- Bid / Lots1.2800/ 12
- Ask / Lots1.4100/ 2
- Open / Previous Close1.2300 / 1.2400
- Day Range
- 52 Week Range
- Volume142,313
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AKTX |
|---|---|---|
| 09:32 ET | 1579 | 1.24 |
| 09:35 ET | 540 | 1.19 |
| 09:37 ET | 360 | 1.19 |
| 09:42 ET | 3279 | 1.15 |
| 09:44 ET | 400 | 1.15 |
| 09:46 ET | 120 | 1.15 |
| 09:48 ET | 100 | 1.15 |
| 09:51 ET | 405 | 1.15 |
| 09:55 ET | 312 | 1.15 |
| 10:00 ET | 590 | 1.1 |
| 10:02 ET | 100 | 1.12 |
| 10:04 ET | 300 | 1.1337 |
| 10:06 ET | 100 | 1.1 |
| 10:09 ET | 200 | 1.1 |
| 10:11 ET | 2200 | 1.1 |
| 10:13 ET | 2109 | 1.12 |
| 10:20 ET | 139 | 1.1201 |
| 10:22 ET | 500 | 1.12 |
| 10:24 ET | 855 | 1.13 |
| 10:26 ET | 3909 | 1.1185 |
| 10:27 ET | 100 | 1.11 |
| 10:31 ET | 100 | 1.11 |
| 10:33 ET | 5940 | 1.11 |
| 10:36 ET | 1707 | 1.12 |
| 10:40 ET | 4645 | 1.1374 |
| 10:42 ET | 1350 | 1.12 |
| 10:45 ET | 200 | 1.11 |
| 10:47 ET | 5271 | 1.11 |
| 10:49 ET | 400 | 1.12 |
| 10:51 ET | 400 | 1.12 |
| 10:54 ET | 100 | 1.12 |
| 10:58 ET | 100 | 1.12 |
| 11:00 ET | 100 | 1.12 |
| 11:02 ET | 100 | 1.12 |
| 11:03 ET | 1100 | 1.1299 |
| 11:05 ET | 3426 | 1.14 |
| 11:12 ET | 200 | 1.15 |
| 11:14 ET | 699 | 1.14 |
| 11:16 ET | 200 | 1.14 |
| 11:20 ET | 200 | 1.14 |
| 11:21 ET | 200 | 1.13 |
| 11:25 ET | 537 | 1.13 |
| 11:27 ET | 5974 | 1.2 |
| 11:32 ET | 100 | 1.15 |
| 11:34 ET | 100 | 1.15 |
| 11:36 ET | 200 | 1.15 |
| 11:39 ET | 2300 | 1.14 |
| 11:41 ET | 100 | 1.14 |
| 11:43 ET | 100 | 1.13 |
| 11:45 ET | 200 | 1.13 |
| 11:50 ET | 500 | 1.1398 |
| 11:52 ET | 700 | 1.14 |
| 11:56 ET | 1000 | 1.17 |
| 11:59 ET | 7101 | 1.18 |
| 12:06 ET | 200 | 1.16 |
| 12:10 ET | 200 | 1.16 |
| 12:14 ET | 200 | 1.16 |
| 12:15 ET | 200 | 1.16 |
| 12:19 ET | 200 | 1.165 |
| 12:21 ET | 8000 | 1.21 |
| 12:24 ET | 200 | 1.18 |
| 12:26 ET | 300 | 1.215 |
| 12:28 ET | 150 | 1.2321 |
| 12:30 ET | 200 | 1.215 |
| 12:32 ET | 4244 | 1.2349 |
| 12:35 ET | 200 | 1.235 |
| 12:39 ET | 200 | 1.235 |
| 12:44 ET | 2066 | 1.2273 |
| 12:46 ET | 300 | 1.235 |
| 12:50 ET | 200 | 1.235 |
| 12:53 ET | 300 | 1.235 |
| 12:55 ET | 100 | 1.235 |
| 01:00 ET | 200 | 1.235 |
| 01:02 ET | 2600 | 1.25 |
| 01:06 ET | 200 | 1.245 |
| 01:09 ET | 200 | 1.24 |
| 01:13 ET | 1101 | 1.24 |
| 01:15 ET | 200 | 1.24 |
| 01:20 ET | 200 | 1.24 |
| 01:22 ET | 404 | 1.25 |
| 01:24 ET | 200 | 1.245 |
| 01:26 ET | 200 | 1.255 |
| 01:27 ET | 728 | 1.26 |
| 01:29 ET | 102 | 1.27 |
| 01:33 ET | 200 | 1.275 |
| 01:36 ET | 200 | 1.275 |
| 01:40 ET | 200 | 1.275 |
| 01:44 ET | 200 | 1.28 |
| 01:45 ET | 200 | 1.28 |
| 01:47 ET | 1612 | 1.3 |
| 01:49 ET | 200 | 1.28 |
| 01:51 ET | 200 | 1.28 |
| 01:54 ET | 100 | 1.28 |
| 01:56 ET | 300 | 1.285 |
| 01:58 ET | 100 | 1.285 |
| 02:00 ET | 200 | 1.285 |
| 02:02 ET | 655 | 1.29 |
| 02:03 ET | 300 | 1.285 |
| 02:05 ET | 536 | 1.285 |
| 02:07 ET | 300 | 1.28 |
| 02:09 ET | 200 | 1.275 |
| 02:12 ET | 300 | 1.275 |
| 02:14 ET | 778 | 1.275 |
| 02:16 ET | 200 | 1.275 |
| 02:18 ET | 6093 | 1.275 |
| 02:20 ET | 200 | 1.275 |
| 02:23 ET | 200 | 1.275 |
| 02:25 ET | 100 | 1.275 |
| 02:27 ET | 100 | 1.275 |
| 02:30 ET | 200 | 1.275 |
| 02:32 ET | 200 | 1.2799 |
| 02:34 ET | 200 | 1.275 |
| 02:38 ET | 200 | 1.275 |
| 02:39 ET | 200 | 1.275 |
| 02:43 ET | 200 | 1.275 |
| 02:45 ET | 100 | 1.275 |
| 02:48 ET | 100 | 1.275 |
| 02:50 ET | 200 | 1.275 |
| 02:54 ET | 200 | 1.275 |
| 02:57 ET | 200 | 1.275 |
| 02:59 ET | 200 | 1.275 |
| 03:01 ET | 150 | 1.2797 |
| 03:03 ET | 200 | 1.275 |
| 03:08 ET | 200 | 1.275 |
| 03:10 ET | 200 | 1.275 |
| 03:14 ET | 200 | 1.275 |
| 03:17 ET | 200 | 1.275 |
| 03:19 ET | 870 | 1.275 |
| 03:21 ET | 500 | 1.275 |
| 03:24 ET | 200 | 1.275 |
| 03:28 ET | 200 | 1.275 |
| 03:30 ET | 5079 | 1.3 |
| 03:33 ET | 300 | 1.285 |
| 03:37 ET | 8200 | 1.28 |
| 03:39 ET | 1200 | 1.3 |
| 03:42 ET | 10000 | 1.3 |
| 03:44 ET | 200 | 1.3 |
| 03:48 ET | 215 | 1.3 |
| 03:50 ET | 204 | 1.3 |
| 03:53 ET | 200 | 1.3 |
| 03:55 ET | 2701 | 1.3 |
| 03:57 ET | 200 | 1.3 |
| 04:00 ET | 1180 | 1.3 |
Nov 19, 2024
Akari Therapeutics Regains Full Nasdaq Compliance, from 8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 14, 2024
Press Release: Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio, from 4:15PM ET on Thursday Nov 14, 2024 by Dow Jones
4:15PM ET on Thursday Nov 14, 2024 by Dow JonesAkari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio, from 4:15PM ET on Thursday Nov 14, 2024 by Dow Jones
4:15PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 8, 2024
Press Release: Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger, from 8:00AM ET on Friday Nov 08, 2024 by Dow Jones
8:00AM ET on Friday Nov 08, 2024 by Dow JonesAkari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger, from 8:00AM ET on Friday Nov 08, 2024 by Dow Jones
8:00AM ET on Friday Nov 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Akari Therapeutics PLC | 32.2M | -0.4x | --- |
KALA BIO Inc | 31.3M | -0.5x | --- |
Lexaria Bioscience Corp | 36.5M | -4.7x | --- |
PolyPid Ltd | 24.1M | -0.5x | --- |
China Health Industries Holdings Inc | 21.3M | -15.6x | --- |
Bright Green Corp | 15.3M | -1.6x | --- |
Company Information
Akari Therapeutics, Plc is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company is engaged in the development of antibody drug conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including geographic atrophy (GA). Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). It is conducting a phase III clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company's pipeline also includes the PH-1 ADC Platform for oncology, PHP-303 program for genetic disease, liver disease and inflammation, specifically for Alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS), including COVID-19.
Contact Information
- Headquarters
- 22 BOSTON WHARF ROAD, FL 7BOSTON, MA, United States 02210
- Phone
- 646-350-0702
- Fax
- 646-843-9352
Executives
- Non-Executive Independent Chairman of the Board
- Hoyoung Huh
- Interim President, Interim Chief Executive Officer, Director
- Samir Patel
- Interim Chief Financial Officer
- Wendy Dicicco
- Independent Director
- Robert Bazemore
- Independent Director
- Michael Grissinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.84 |
EPS | $-2.98 |
Book Value | $-0.03 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
